Tech Company M&A Transactions
Alantos Pharmaceuticals Holding Acquisition
Headquartered in Cambridge, Alantos Pharmaceuticals Holding was acquired by Amgen. The acquisition price was $300 million.
Transaction Overview
Company Name
Acquired By
Announced On
6/6/2007
Transaction Type
M&A
Amount
$300,000,000
M&A Terms
Under terms of the agreement, Amgen will pay $300 million in cash to acquire Alantos. Following completion of the transaction, Alantos will become a wholly-owned subsidiary of Amgen.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Alantos Pharmaceuticals is a chemistry-driven discovery company with a proprietary pipeline of small molecule drugs focused in the area of inflammation and diabetes. Its two lead compounds are in pre-clinical development for Osteoarthritis and type II diabetes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Frank Douglas
Browse more venture capital transactions:
Prev: 6/6/2007: NextBio venture capital transaction
Next: 6/6/2007: Biovigilant venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs